BioSpace News Archive

DaVita Kidney Care, a division of DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States, celebrates its more than 18,000 nephrology nurses across the U.S. and in 10 other countries around the world during Nephrology Nurses Week.

Using food as fuel, American author, entrepreneur, philanthropist and life coach, Tony Robbins thought that by eating mostly swordfish and tuna, he was giving his body the proper nutrients for his active lifestyle.

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed immuno-oncology expert Richard Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies at Johns Hopkins Kimmel Cancer Center, to its scientific advisory board

Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company’s immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the FDA-approved PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.

A year after Wamberg Genomic Advisors introduced Cancer Guardian, a program that provides guidance and access to leading-edge advanced DNA testing at the time of a cancer diagnosis, the company announced that Cancer Guardian will now include enhanced Comprehensive Cancer Support.

Minnetronix, Inc. , a leading medical technology and solutions provider, today announced that it has rebranded as Minnetronix Medical, Inc.

itan Pharmaceuticals, Inc.. (NASDAQ: TTNP) today announced that it has been awarded a two year grant of approximately $6.7 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty (“PCT”) application pertaining to the Company’s proprietary biosynthesis program

IDEXX Laboratories, Inc., (NASDAQ: IDXX), the global leader in rapid microbiological testing for water, today announced that the IDEXX Pseudalert® method has been published as the International Organization for Standardization (ISO) worldwide standard 16266-2 for the 24-hour detection of Pseudomonas aeruginosa in water.

CustomWeather, Inc., a premier, specialized provider of high-resolution weather data and alert services, announced that it has launched its new Weather Data API Commerce Site, created specifically for developers.